BioMarin Pharmaceutical’s Voxzogo (vosoritide) injection received approval by the FDA (Food and Drug Administration) on November 19, 2021, to manage Dwarfism in children. It can now be used to improve growth in children aged above 5 years who are suffering from open epiphyses (growth plates) and achondroplasia (short-limbed dwarfism). This means that such patients can still manage the condition and grow. Earlier in August 2021, Voxzogo (vosoritide) injection received approval for use in Europe. 

The approval of VOXZOGO injection was based on the results of a double-blind,...